Publication at First Faculty of Medicine |
2010
Abstract
Glitazones are antidiabetic drugs acting through the stimulation of nuclear PPAR (peroxisome proliferator activated receptors) receptors. Due to pleiotropic effects of PPAR activation glitazones not only improve blood glucose and insulin resistance but also exert antiinflammatory, blood pressure lowering and numerous other positive effects.
In addition to benefitial effects of glitazones possible cardiovascular side effects in patients with coronary heart disease are discussed especially in connection with rosiglitazone. The aim of this article is to summarize the results of recent trials with rosiglitazone in patients with cardiovascular complications.